[go: up one dir, main page]

BR9713536A - Compostos heterocìclicos de guanidinila úteis como agonistas de adrenoceptores alfa-2 - Google Patents

Compostos heterocìclicos de guanidinila úteis como agonistas de adrenoceptores alfa-2

Info

Publication number
BR9713536A
BR9713536A BR9713536-4A BR9713536A BR9713536A BR 9713536 A BR9713536 A BR 9713536A BR 9713536 A BR9713536 A BR 9713536A BR 9713536 A BR9713536 A BR 9713536A
Authority
BR
Brazil
Prior art keywords
alpha
compounds
heterocyclic
compounds useful
adrenoceptor agonists
Prior art date
Application number
BR9713536-4A
Other languages
English (en)
Inventor
Thomas Lee Cupps
Sophie Eva Bogdan
Raymond Todd Henry
Russell James Sheldon
William Lee Seibel
Jeffrey Joseph Ares
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BR9713536A publication Critical patent/BR9713536A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Patente de Invenção: <B>"COMPOSTOS HETEROCìCLICOS DE GUANIDILINA E COMPOSIçãO FARMACêUTICA"<D>. Esta invenção refere-se a compostos tendo estruturas (l) conforme descrito nas reivindicações; e enantiómeros, isómeros ópticos, estereoisómeros, diastereómeros, tautómeros, sais de adição, amidas bio-hidrolisáveis e seus ésteres, bem como composições farmacêuticas contendo tais compostos. A invenção também refere-se ao uso de tais compostos para prevenir ou tratar distúrbios modulados por adrenoceptores alfa-2.
BR9713536-4A 1996-11-25 1997-11-21 Compostos heterocìclicos de guanidinila úteis como agonistas de adrenoceptores alfa-2 BR9713536A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3202396P 1996-11-25 1996-11-25
PCT/US1997/020802 WO1998023596A1 (en) 1996-11-25 1997-11-21 Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists

Publications (1)

Publication Number Publication Date
BR9713536A true BR9713536A (pt) 2000-11-07

Family

ID=21862692

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713536-4A BR9713536A (pt) 1996-11-25 1997-11-21 Compostos heterocìclicos de guanidinila úteis como agonistas de adrenoceptores alfa-2

Country Status (25)

Country Link
US (3) US6225331B1 (pt)
EP (1) EP0944604B1 (pt)
JP (1) JP2001506600A (pt)
KR (1) KR20000069131A (pt)
CN (1) CN1104422C (pt)
AR (1) AR009145A1 (pt)
AT (1) ATE286885T1 (pt)
AU (1) AU730369B2 (pt)
BR (1) BR9713536A (pt)
CA (1) CA2272640C (pt)
CO (1) CO4910148A1 (pt)
CZ (1) CZ184099A3 (pt)
DE (1) DE69732244T2 (pt)
ES (1) ES2236833T3 (pt)
HU (1) HUP0000312A3 (pt)
ID (1) ID23857A (pt)
IL (1) IL130077A0 (pt)
NO (1) NO313912B1 (pt)
NZ (1) NZ336010A (pt)
PE (1) PE16399A1 (pt)
RU (1) RU2194700C2 (pt)
SK (1) SK69799A3 (pt)
TR (1) TR199901468T2 (pt)
WO (1) WO1998023596A1 (pt)
ZA (1) ZA9710578B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU730369B2 (en) 1996-11-25 2001-03-08 Board Of Regents Of The University Of Nebraska, The Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
US6291514B1 (en) * 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
DZ3415A1 (fr) * 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
CA2419653A1 (en) * 2000-09-08 2002-03-14 Warner-Lambert Company Prevention of acute sinusitis and sinus attack
DE60216747T2 (de) * 2001-04-09 2007-10-04 Novartis Vaccines and Diagnostics, Inc., Emeryville Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
US20030195187A1 (en) * 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
US20050124652A1 (en) * 2002-02-04 2005-06-09 Rustum Boyce Guanidino compounds
US20030207814A1 (en) * 2002-02-04 2003-11-06 Chiron Corporation Novel guanidinyl derivatives
EP1487474A4 (en) * 2002-02-25 2006-11-29 Chiron Corp INTRANASAL ADMINISTRATION OF MC4-R AGONISTS
CA2486966A1 (en) * 2002-05-23 2003-12-04 Chiron Corporation Substituted quinazolinone compounds
EP1651229A1 (en) * 2003-05-23 2006-05-03 Chiron Corporation Guanidino-substituted quinazolinone compounds as mc4-r agonists
RU2254855C2 (ru) * 2003-09-10 2005-06-27 Открытое акционерное общество "Акционерное курганское общество медицинских препаратов и изделий "Синтез" Противовирусное средство и способ его получения
JP2007511612A (ja) * 2003-11-19 2007-05-10 カイロン コーポレイション 減少された生体蓄積を有するキナゾリノン化合物
KR20130136010A (ko) * 2005-04-13 2013-12-11 네우렉슨 인코포레이티드 Ｎｏｓ 저해 활성을 갖는 치환된 인돌 화합물
EP2218442A1 (en) 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
CL2008000838A1 (es) * 2007-03-23 2008-10-10 Neuraxon Inc Compuestos derivados de quinolina y tetrahidroquinolina, con actividad inhibidora nos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un dolor de cabeza tal como migrana, dolor cronico, desordenes del sistema nervios
EP2220074A4 (en) * 2007-11-16 2012-01-04 Neuraxon Inc 3,5-SUBSTITUTED INDOL COMPOUNDS WITH NOS AND NOREPINEPHRINE RECOVERY-HEMDERING EFFECT
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
GB0919889D0 (en) * 2009-11-13 2009-12-30 Biocopea Ltd Drug composition and its use in therapy
JP5959537B2 (ja) * 2011-01-28 2016-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ピリジニル−ピリミジン及び医薬としてのその使用
CN112047947A (zh) * 2020-10-13 2020-12-08 石药集团新诺威制药股份有限公司 一种茶碱的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU148414A1 (ru) * 1961-07-03 1961-11-30 Е.Н. Зильберман Способ получени имидазолов и оксазолов
US3908013A (en) 1970-09-17 1975-09-23 Armour Pharma Pharmaceutical aromatic guanidine compositions and methods of using same
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US3947455A (en) 1974-04-15 1976-03-30 Armour Pharmaceutical Company 5'-(8'-Hydroxyquinolyl)guanidine compounds
US4000279A (en) 1974-10-29 1976-12-28 Armour Pharmaceutical Company Pharmaceutical preparations containing 5'-(8'-hydroxyquinolyl)guanidine compounds and methods of using same
KR860002082A (ko) * 1984-08-29 1986-03-26 프랑시스 글로리 자기 변환기 헤드 구조물
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
FI962493L (fi) * 1993-12-17 1996-07-26 Procter & Gamble Alfa-2-adrenoseptoriagonisteina käyttökelpoisia 6-(2-imidatsolinyyliamino)kinoksaliiniyhdisteitä
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
AU730369B2 (en) 1996-11-25 2001-03-08 Board Of Regents Of The University Of Nebraska, The Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
AU5330698A (en) * 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors

Also Published As

Publication number Publication date
CA2272640A1 (en) 1998-06-04
US20010000345A1 (en) 2001-04-19
ES2236833T3 (es) 2005-07-16
WO1998023596A1 (en) 1998-06-04
CO4910148A1 (es) 2000-04-24
HUP0000312A2 (hu) 2000-09-28
ID23857A (id) 2000-05-25
AR009145A1 (es) 2000-03-08
CN1104422C (zh) 2003-04-02
NO992498D0 (no) 1999-05-25
JP2001506600A (ja) 2001-05-22
IL130077A0 (en) 2000-02-29
NZ336010A (en) 2001-05-25
TR199901468T2 (xx) 1999-10-21
US6391878B2 (en) 2002-05-21
AU730369B2 (en) 2001-03-08
RU2194700C2 (ru) 2002-12-20
EP0944604A1 (en) 1999-09-29
CZ184099A3 (cs) 1999-11-17
NO992498L (no) 1999-07-26
KR20000069131A (ko) 2000-11-25
NO313912B1 (no) 2002-12-23
AU5438198A (en) 1998-06-22
DE69732244D1 (de) 2005-02-17
DE69732244T2 (de) 2006-06-29
PE16399A1 (es) 1999-03-12
SK69799A3 (en) 2000-06-12
CA2272640C (en) 2003-07-08
HUP0000312A3 (en) 2001-12-28
US20020128481A1 (en) 2002-09-12
US6225331B1 (en) 2001-05-01
ZA9710578B (en) 1998-06-25
CN1242006A (zh) 2000-01-19
ATE286885T1 (de) 2005-01-15
EP0944604B1 (en) 2005-01-12

Similar Documents

Publication Publication Date Title
BR9713536A (pt) Compostos heterocìclicos de guanidinila úteis como agonistas de adrenoceptores alfa-2
TR199901885T2 (xx) Alfa-2 adrenosept�r agonistleri olarak yararl� 2-imidazolinilaminoindol bile�ikleri.
BR9712085A (pt) Inibidores de metaloprotease heterocìclicos
BR0014078A (pt) Inibidores de fator xa
BRPI9810519A (pt) derivados de 4&#39;&#39;-substituído-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.
BR9810097A (pt) Derivados de macrolìdeos c-4-substituìdos
BR9608041B8 (pt) Oligossacarídeo sulfatado, e, composição farmacêutica ou veterinária para tratamento anti-angiogênico, anti-metastático e/ou anti-inflamatório.
DK0816376T3 (da) Thrombininhibitorer som antikoagulante midler
ITPD920071A1 (it) Impiego di preparazioni di acido ialuronico per la formazione di tessuto osseo
DK0801948T3 (da) Oftalmisk sammensætning med forlænget opholdstid i øjet
BR9401241A (pt) Composição aquosa para tratamento de feridas e processo para formar a mesma
BR9713178A (pt) Inbidores espirocìclicos da metaloprotease.
BR9914998A (pt) Antibióticos macrólidos
BRPI9915480B8 (pt) azalídeos de 13 membros, composições farmacêuticas compreendendo os mesmos, método para sua preparação bem como seus usos.
TR199901486T2 (xx) Alfa-2 adrenosept�r agonistleri olarak yararl� 2-imidazolinilamino-benzoksazol bile�ikleri.
ES2160649T3 (es) Nuevos compuestos lactamicos y procedimientos para su preparacion.
BR0109348A (pt) Inibidores de metaloproteases n-substituìdos os quais contêm cadeias laterais carbocìclicas
CO4340690A1 (es) Los derivados de la quinolonilcarboxamidocefalosporina y las composiciones farmaceuticas que las contienen
BR9916320A (pt) Bisamido polibiguanidas e uso das mesmas para desinfetar lentes de contato e preservar composições farmacêuticas
EP1065200A4 (en) Aminoisoquinoline DERIVATIVES
BR9808904A (pt) Composto 5-(2-imidazolinilamino)benzimidazol úteis como agonistas adrenoceptores-alfa-2
BR9909268A (pt) C11 oximil e hidroxilamino prostaglandinas úteis como agonistas de fp
BR9714362A (pt) agonistas de alfa-2 adrenoceptores
AR023644A1 (es) 3-aril-pirazoles substituidos, procedimiento para su obtencion, procedimiento para la lucha contra plantas indeseables, empleo de los mismos contra plantasindeseables y/o como fungicida, y composicion para el tratamiento de plantas
ES2076838T3 (es) Nuevo derivado de la isoindolinona, su preparacion y las composiciones farmaceuticas que le contienen.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1861 DE 05/09/2006.